Skip to content

Study on the Efficacy and Neural Mechanisms of Dual-Target rTMS Regulating Neuropathic Pain based on Sequential Stimulation of DLPFC and M1

Study on the Efficacy and Neural Mechanisms of Dual-Target rTMS Regulating Neuropathic Pain based on Sequential Stimulation of DLPFC and M1

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500114265
Enrollment
Unknown
Registered
2025-12-09
Start date
2025-12-12
Completion date
Unknown
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuropathic Pain

Interventions

Trial group:Sequential rTMS stimulation targeting the dorsolateral prefrontal cortex (DLPFC) followed by the primary motor cortex (M1)
Control group:All participants received M1 stimulation combined with sham stimulation of the DLPFC using the coil tilting method
all subjects underwent a 5-day treatment course and were assessed multidimensionally using clinical scales and TMS-EEG techniques at baseline, post-treatment, and at a 1-month follow-up.

Sponsors

Hangzhou Third People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age over 18, gender not limited; 2. Meets the diagnostic criteria for neuropathic pain established by the International Association of Pain Societies (IASP); 3. Within one week prior to enrollment, the average daily pain intensity rating scale (NRS) score was >= 4 points; 4.Having normal understanding and communication skills, able to complete research related questionnaire filling and evaluation processes; 5.Voluntarily participate in this study and sign a written informed consent form approved by the ethics committee.

Exclusion criteria

Exclusion criteria: 1.Taboos for TMS examination; 2.Individuals who have previously suffered from mental illnesses, aphasia, or dementia; 3. Individuals with severe cardiopulmonary dysfunction, extreme weakness, and inability to cooperate with rehabilitation assessment and treatment; 4.Suffering from other diseases that may interfere with research results, such as epilepsy (including idiopathic epilepsy, symptomatic epilepsy, even if there have been no seizures in the past 5 years) or a family history of epilepsy. 5.Pregnant or lactating women; 6.Patients who are currently participating in other clinical studies or using other experimental drugs for treatment.

Design outcomes

Primary

MeasureTime frame
Neuroelectrophysiology;Numerical Rating Scale for Pain Intensity;

Secondary

MeasureTime frame
Neuropsychology;

Countries

China

Contacts

Public ContactYan Yongxing

Hangzhou Third People's Hospital

yyxing12@163.com+86 571 87823154

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026